title: Technology evaluation: pertuzumab, Roche/Genentech/Chugai.
abstract: Genentech, Roche and Chugai are developing pertuzumab, a next-generation trastuzumab-like molecule (an anti-HER/neu monoclonal antibody), for the potential treatment of cancer. Pertuzumab is currently undergoing phase II clinical trials.
authors.affiliation: Guy's Hospital, Department of Medical Oncology, 3rd Floor, New Guy's House, St Thomas Street, London SE1 7EH, UK. James.Spicer@gstt.nhs.uk
authors.forename: James
authors.initials: J
authors.lastname: Spicer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000276:immunology; D051379:Mice; D041681:NIH 3T3 Cells; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010330:Patents as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; C485206:pertuzumab